|
|
Sanofi-Aventis is the largest European pharmaceutical group. Net sales per product family break down as follows:
- pharmaceutical products (88,1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs;
- human vaccines (11.9%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2009, the group had 72 production sites throughout the world.
Net sales are distributed geographically as follows: France (10.9%), Europe (30.2%), the United States (32.2%), and other (26.7%).
|
|
|
|
- Executive VP Research & Development :
Marc Cluzel |
- Executive VP, Pharmaceutical Operations :
Hanspeter Spek |
- Chairman of the Board :
Serge Weinberg |
- Executive VP, Chief Financial Officer :
Jérôme Contamine |
- Chief Executive Officer :
Christopher A. Viehbacher |
- Investor Relations :
Sebastien Martel |
- Senior VP, Vaccines :
Wayne Pisano |
- Senior VP, Legal Affairs and General Counsel :
Karen Linehan |
- Senior VP, Industrial Affairs :
Philippe Luscan |
- Senior VP, Human Resources :
Roberto Pucci |
|
|
|
|
| - Other shareholders |
81,61% |
| - L'Oréal |
8,97% |
| - Total |
5,88% |
| - Employees |
1,38% |
| - Company-owned shares |
0,71% |
|
|
|
|
|
- PEA / SRD eligible : YES / YES - Euronext Paris - Eurolist compartiment A - CAC 40 / CAC AllShares, Euronext 100, EuroStoxx 50, Eurotop 100, Stoxx 50 |
|
|
|
|
| - ISIN Code : |
FR0000120578 |
| - Bloomberg Code : |
SAN:FP |
| - Reuters Code : |
SASY.PA |
| - Datastream Code : |
F:SQ@F |
|
| Company contact information |
|
174 avenue de France
75013 Paris
France
Phone : +33 (0)1 53 77 40 00
Fax : +33 (0)1 53 77 44 63
Internet : http://www.sanofi-aventis.com
|
|
Financial data source :
© 2010 Cofisem |
|
|
|
|
